Gain Therapeutics, Inc. (GANX) analyst actions
Rating and price-target actions on GANX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the GANX overview →
2 measured GANX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease | Press release | -1.50% | -1.26% | |
| Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease | Press release | +1.29% | +2.17% |
Keep exploring
More GANX: earnings → · SEC filings → · GANX overview →